Tripodi Armando, Padovan Lidia, Veena Chantarangkul, Scalambrino Erica, Testa Sophie, Peyvandi Flora
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, MiIano, ltaly; IRCCS Cà Granda Maggiore Hospital Foundation, Milano, Italy.
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, MiIano, ltaly; IRCCS Cà Granda Maggiore Hospital Foundation, Milano, Italy.
Thromb Res. 2015 Jun;135(6):1186-90. doi: 10.1016/j.thromres.2015.03.032. Epub 2015 Apr 9.
Apixaban is a direct oral anticoagulant (DOAC) targeting factor Xa and thus quenching thrombin generation and clot formation. However, little information is available on the influence that apixaban may have on the parameters of thrombin generation.
Aliquots of a pooled normal plasma have been added with increased concentrations of purified apixaban and were used to assess the degree of modification brought about by the drug on the basic tests of coagulation prothrombin and activated partial thromboplastin time (PT and APTT) and on thrombin generation parameters.
The study shows that while apixaban has little effect on PT or APTT it does affect all the parameters of thrombin generation, including the lag-time (which is increased), the endogenous thrombin potential (ETP) and thrombin-peak (both decreased although to a different extent), and the velocity index (decreased). Interestingly, the above effects were more pronounced when the measurements were recorded in the presence of thrombomodulin, thus making the ratio (with/without thrombomodulin) to decrease consistently as a function of the apixaban concentrations.
These findings support the antithrombotic properties of apixaban and can help to understand the mechanism(s) of action of this drug. Thrombin generation could be used as a convenient laboratory tool to assess the anticoagulant activity of other drugs and to make between-DOAC comparison.
阿哌沙班是一种直接口服抗凝剂(DOAC),作用于凝血因子Xa,从而抑制凝血酶生成和血栓形成。然而,关于阿哌沙班对凝血酶生成参数的影响,目前所知甚少。
向混合正常血浆的等分试样中加入浓度递增的纯化阿哌沙班,用于评估该药物对凝血酶原基本检测(凝血酶原时间,PT)和活化部分凝血活酶时间(APTT)以及凝血酶生成参数的改变程度。
研究表明,虽然阿哌沙班对PT或APTT影响不大,但它确实会影响所有凝血酶生成参数,包括滞后时间(延长)、内源性凝血酶潜力(ETP)和凝血酶峰值(均降低,但程度不同)以及速度指数(降低)。有趣的是,当在血栓调节蛋白存在的情况下进行测量时,上述影响更为明显,从而使(有/无血栓调节蛋白时的)比值随着阿哌沙班浓度的增加而持续降低。
这些发现支持了阿哌沙班的抗血栓特性,并有助于理解该药物的作用机制。凝血酶生成可作为一种便捷的实验室工具,用于评估其他药物的抗凝活性以及进行不同DOAC之间的比较。